|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
This retrospective analysis of inpatient data obtained from administrative and electronic medical records will investigate the role of empiric antibiotics on admission on the mortality for non-intubated patients presenting with Novel Coronavirus Diseases 2019 (COVID-19) associated pneumonia without extra-pulmonary sources of infection or septic shock.
Description: Death during the hospitalization or discharge to hospiceMeasure: In-Hospital Mortality or discharge to hospice Time: From time of admission to death during the hospitalization or discharge to hospice
Description: Mechanical ventilation initiated after 48 hours into the admission as a marker of clinical deterioration and its relationship to receipt of empiric antibioticMeasure: Rates of Mechanical Ventilation Time: From 48 hours post admission to discharge or death
Description: Identify the risk of C. difficile infection on patients according to empiric therapy status as captured by diagnosis codes not present-on-admissionMeasure: Rates of C. difficile infection Time: not present-on-admission
Description: As a marker of morbidity and and its relationship to receipt of empiric antibiotic therapyMeasure: Length of stay for survivors Time: From admission to discharge (not to hospice)
Description: As a marker of clinical deterioration and its relationship to receipt of empiric antibiotic therapy among patients who did not require ICU admission upon arrivalMeasure: Rates of ICU Admission Time: From 48 hours post admission to discharge
Description: Identify the risk of acute kidney injury according to empiric therapy status as captured by diagnosis codes not present-on-admissionMeasure: Rates of Acute Kidney Injury Time: not present-on-admission
Description: For patients in hospital for at least 5 daysMeasure: Days free of antibiotics Time: 5 days from admission to discharge or primary outcome
Description: As above, as captured by diagnosis codes not present-on-admissionMeasure: Rates of secondary infections due to antibiotic resistant pathogens Time: not present-on-admission
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports